A phase I trial of chlorambucil administered in short pulses in patients with advanced malignancies

Martin S. Blumenreich, Thomas M. Woodcock, Eliza J. Sherrill, Stephen P Richman, Patrick S. Gentile, Barbara E. Epremian, Thomas T. Kubota, Joseph C. Allegra

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We carried out a phase I trial with chlorambucil. Thirty patients with advanced cancer were entered in six dose levels: 36, 48, 60, 84, 108, and 144 mg/m2. The drug was given in six divided oral doses every 6 hours and the regimen was repeated every 3 weeks. The median age was 62 years (31-84), median Kamofsky performance status (KPS) 60 (40-90). All patients but one had received prior radiation therapy, chemotherapy, or both. Central nervous system toxicity was dose limiting, occurring in 5 of 6 patients at 144 mg/m2. It was characterized by transient seizures, hallucinations, lethargy, stupor, and coma. Metoclopramide was successful in controlling nausea and vomiting, which was severe if the antiemetic was not used. Leukopenia (3 patients) and thrombocytopenia (2 patients) were mild. One patient with colorectal carcinoma had a minor response, and two patients with non-small cell lung cancer had stable disease. A safe dose for phase II trials is 108 mg/m2 in six 6-hourly oral doses.

Original languageEnglish
Pages (from-to)371-375
Number of pages5
JournalCancer Investigation
Volume6
Issue number4
DOIs
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Chlorambucil
Neoplasms
Stupor
Lethargy
Metoclopramide
Antiemetics
Hallucinations
Leukopenia
Coma
Non-Small Cell Lung Carcinoma
Nausea
Vomiting
Colorectal Neoplasms
Seizures
Radiotherapy
Central Nervous System
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Blumenreich, M. S., Woodcock, T. M., Sherrill, E. J., Richman, S. P., Gentile, P. S., Epremian, B. E., ... Allegra, J. C. (1988). A phase I trial of chlorambucil administered in short pulses in patients with advanced malignancies. Cancer Investigation, 6(4), 371-375. https://doi.org/10.3109/07357908809080064

A phase I trial of chlorambucil administered in short pulses in patients with advanced malignancies. / Blumenreich, Martin S.; Woodcock, Thomas M.; Sherrill, Eliza J.; Richman, Stephen P; Gentile, Patrick S.; Epremian, Barbara E.; Kubota, Thomas T.; Allegra, Joseph C.

In: Cancer Investigation, Vol. 6, No. 4, 01.01.1988, p. 371-375.

Research output: Contribution to journalArticle

Blumenreich, MS, Woodcock, TM, Sherrill, EJ, Richman, SP, Gentile, PS, Epremian, BE, Kubota, TT & Allegra, JC 1988, 'A phase I trial of chlorambucil administered in short pulses in patients with advanced malignancies', Cancer Investigation, vol. 6, no. 4, pp. 371-375. https://doi.org/10.3109/07357908809080064
Blumenreich, Martin S. ; Woodcock, Thomas M. ; Sherrill, Eliza J. ; Richman, Stephen P ; Gentile, Patrick S. ; Epremian, Barbara E. ; Kubota, Thomas T. ; Allegra, Joseph C. / A phase I trial of chlorambucil administered in short pulses in patients with advanced malignancies. In: Cancer Investigation. 1988 ; Vol. 6, No. 4. pp. 371-375.
@article{199c9c0388b24558a5b05d4b5edee927,
title = "A phase I trial of chlorambucil administered in short pulses in patients with advanced malignancies",
abstract = "We carried out a phase I trial with chlorambucil. Thirty patients with advanced cancer were entered in six dose levels: 36, 48, 60, 84, 108, and 144 mg/m2. The drug was given in six divided oral doses every 6 hours and the regimen was repeated every 3 weeks. The median age was 62 years (31-84), median Kamofsky performance status (KPS) 60 (40-90). All patients but one had received prior radiation therapy, chemotherapy, or both. Central nervous system toxicity was dose limiting, occurring in 5 of 6 patients at 144 mg/m2. It was characterized by transient seizures, hallucinations, lethargy, stupor, and coma. Metoclopramide was successful in controlling nausea and vomiting, which was severe if the antiemetic was not used. Leukopenia (3 patients) and thrombocytopenia (2 patients) were mild. One patient with colorectal carcinoma had a minor response, and two patients with non-small cell lung cancer had stable disease. A safe dose for phase II trials is 108 mg/m2 in six 6-hourly oral doses.",
author = "Blumenreich, {Martin S.} and Woodcock, {Thomas M.} and Sherrill, {Eliza J.} and Richman, {Stephen P} and Gentile, {Patrick S.} and Epremian, {Barbara E.} and Kubota, {Thomas T.} and Allegra, {Joseph C.}",
year = "1988",
month = "1",
day = "1",
doi = "10.3109/07357908809080064",
language = "English",
volume = "6",
pages = "371--375",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - A phase I trial of chlorambucil administered in short pulses in patients with advanced malignancies

AU - Blumenreich, Martin S.

AU - Woodcock, Thomas M.

AU - Sherrill, Eliza J.

AU - Richman, Stephen P

AU - Gentile, Patrick S.

AU - Epremian, Barbara E.

AU - Kubota, Thomas T.

AU - Allegra, Joseph C.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - We carried out a phase I trial with chlorambucil. Thirty patients with advanced cancer were entered in six dose levels: 36, 48, 60, 84, 108, and 144 mg/m2. The drug was given in six divided oral doses every 6 hours and the regimen was repeated every 3 weeks. The median age was 62 years (31-84), median Kamofsky performance status (KPS) 60 (40-90). All patients but one had received prior radiation therapy, chemotherapy, or both. Central nervous system toxicity was dose limiting, occurring in 5 of 6 patients at 144 mg/m2. It was characterized by transient seizures, hallucinations, lethargy, stupor, and coma. Metoclopramide was successful in controlling nausea and vomiting, which was severe if the antiemetic was not used. Leukopenia (3 patients) and thrombocytopenia (2 patients) were mild. One patient with colorectal carcinoma had a minor response, and two patients with non-small cell lung cancer had stable disease. A safe dose for phase II trials is 108 mg/m2 in six 6-hourly oral doses.

AB - We carried out a phase I trial with chlorambucil. Thirty patients with advanced cancer were entered in six dose levels: 36, 48, 60, 84, 108, and 144 mg/m2. The drug was given in six divided oral doses every 6 hours and the regimen was repeated every 3 weeks. The median age was 62 years (31-84), median Kamofsky performance status (KPS) 60 (40-90). All patients but one had received prior radiation therapy, chemotherapy, or both. Central nervous system toxicity was dose limiting, occurring in 5 of 6 patients at 144 mg/m2. It was characterized by transient seizures, hallucinations, lethargy, stupor, and coma. Metoclopramide was successful in controlling nausea and vomiting, which was severe if the antiemetic was not used. Leukopenia (3 patients) and thrombocytopenia (2 patients) were mild. One patient with colorectal carcinoma had a minor response, and two patients with non-small cell lung cancer had stable disease. A safe dose for phase II trials is 108 mg/m2 in six 6-hourly oral doses.

UR - http://www.scopus.com/inward/record.url?scp=0023717469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023717469&partnerID=8YFLogxK

U2 - 10.3109/07357908809080064

DO - 10.3109/07357908809080064

M3 - Article

C2 - 3179770

AN - SCOPUS:0023717469

VL - 6

SP - 371

EP - 375

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 4

ER -